NTK had filed a claim in October 2023, seeking damages of 20 billion yen from Daiichi Sankyo for allegedly obstructing its efforts to complete its open offers to acquire shares in Indian hospital ...

from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with ...

IHH Healthcare said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi Sankyo over its Fortis Healthcare stake buy to up to 109.3 billion rupees ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

Japanese drugmaker Daiichi Sankyo has been a sponsor of the National Cherry Blossom Festival in Washington, D.C. since 1909 — when the company’s first president, Dr. Jokichi Takamine, donated 3,000 ...

In January 2025, Daiichi Sankyo reported FY2024 Q3 revenue of ¥1,367.6 billion [~$9.16 billion], up 16.6% YoY, with core operating profit rising to ¥229.0 billion [~$1.53 billion] (+33.0%).

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave its thumbs-up to eight new medicines ... AstraZeneca and Daiichii Sankyo’s antibody-drug conjugate ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti ...